Phaseline

Companies › Minerva Biotechnologies

Minerva Biotechnologies: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jan 2035.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
huMNC2-CAR44 CAR T cells
Anti-MUC1* (cleaved MUC1) CAR T cell therapy
MUC1Phase 1Metastatic Breast CancerJan 2035

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04020575huMNC2-CAR44 CAR T cellsPhase 1Metastatic Breast CancerOncologyJan 2035
NCT04020575huMNC2-CAR44 CAR T cellsPhase 1Metastatic Breast CancerOncologyJan 2035

Targets

MUC1 (1)

Companies with the same targets

Poseida Therapeutics Beijing Biotech NEOK Bio

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.